586 related articles for article (PubMed ID: 23754736)
1. Population pharmacokinetics of sifalimumab, an investigational anti-interferon-α monoclonal antibody, in systemic lupus erythematosus.
Narwal R; Roskos LK; Robbie GJ
Clin Pharmacokinet; 2013 Nov; 52(11):1017-27. PubMed ID: 23754736
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetic analysis of sifalimumab from a clinical phase IIb trial in systemic lupus erythematosus patients.
Zheng B; Yu XQ; Greth W; Robbie GJ
Br J Clin Pharmacol; 2016 May; 81(5):918-28. PubMed ID: 26659791
[TBL] [Abstract][Full Text] [Related]
3. Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study.
Petri M; Wallace DJ; Spindler A; Chindalore V; Kalunian K; Mysler E; Neuwelt CM; Robbie G; White WI; Higgs BW; Yao Y; Wang L; Ethgen D; Greth W
Arthritis Rheum; 2013 Apr; 65(4):1011-21. PubMed ID: 23400715
[TBL] [Abstract][Full Text] [Related]
4. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study.
Merrill JT; Wallace DJ; Petri M; Kirou KA; Yao Y; White WI; Robbie G; Levin R; Berney SM; Chindalore V; Olsen N; Richman L; Le C; Jallal B; White B;
Ann Rheum Dis; 2011 Nov; 70(11):1905-13. PubMed ID: 21798883
[TBL] [Abstract][Full Text] [Related]
5. Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study.
Khamashta M; Merrill JT; Werth VP; Furie R; Kalunian K; Illei GG; Drappa J; Wang L; Greth W;
Ann Rheum Dis; 2016 Nov; 75(11):1909-1916. PubMed ID: 27009916
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and Pharmacodynamics of JNJ-55920839, an Antibody Targeting Interferon α/ω, in Healthy Subjects and Subjects with Mild-to-Moderate Systemic Lupus Erythematosus.
Yao Z; Loggia L; Fink D; Chevrier M; Marciniak S; Sharma A; Xu Z
Clin Drug Investig; 2020 Dec; 40(12):1127-1136. PubMed ID: 33085033
[TBL] [Abstract][Full Text] [Related]
7. Population Pharmacokinetics of ABT-806, an Investigational Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody, in Advanced Solid Tumor Types Likely to Either Over-Express Wild-Type EGFR or Express Variant III Mutant EGFR.
Sharma S; Mittapalli RK; Holen KD; Xiong H
Clin Pharmacokinet; 2015 Oct; 54(10):1071-81. PubMed ID: 25761639
[TBL] [Abstract][Full Text] [Related]
8. A guide to rational dosing of monoclonal antibodies.
Bai S; Jorga K; Xin Y; Jin D; Zheng Y; Damico-Beyer LA; Gupta M; Tang M; Allison DE; Lu D; Zhang Y; Joshi A; Dresser MJ
Clin Pharmacokinet; 2012 Feb; 51(2):119-35. PubMed ID: 22257150
[TBL] [Abstract][Full Text] [Related]
9. Refinement of the population pharmacokinetic model for the monoclonal antibody matuzumab: external model evaluation and simulations.
Kuester K; Kovar A; Lüpfert C; Brockhaus B; Kloft C
Clin Pharmacokinet; 2009; 48(7):477-87. PubMed ID: 19691369
[TBL] [Abstract][Full Text] [Related]
10. Safety and tolerability of sifalimumab, an anti-interferon-α monoclonal antibody, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study.
Takeuchi T; Tanaka Y; Matsumura R; Saito K; Yoshimura M; Amano K; Atsumi T; Suematsu E; Hayashi N; Wang L; Tummala R
Mod Rheumatol; 2020 Jan; 30(1):93-100. PubMed ID: 30791804
[No Abstract] [Full Text] [Related]
11. Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours.
Gibiansky L; Sutjandra L; Doshi S; Zheng J; Sohn W; Peterson MC; Jang GR; Chow AT; Pérez-Ruixo JJ
Clin Pharmacokinet; 2012 Apr; 51(4):247-60. PubMed ID: 22420579
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors.
Yoshiba S; Jansen M; Matsushima N; Chen S; Mendell J
Cancer Chemother Pharmacol; 2016 May; 77(5):987-96. PubMed ID: 27017616
[TBL] [Abstract][Full Text] [Related]
13. Nonlinear Population Pharmacokinetics of Anifrolumab in Healthy Volunteers and Patients With Systemic Lupus Erythematosus.
Almquist J; Kuruvilla D; Mai T; Tummala R; White WI; Tang W; Roskos L; Chia YL
J Clin Pharmacol; 2022 Sep; 62(9):1106-1120. PubMed ID: 35383948
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of golimumab in patients with ankylosing spondylitis: impact of body weight and immunogenicity.
Xu ZH; Lee H; Vu T; Hu C; Yan H; Baker D; Hsu B; Pendley C; Wagner C; Davis HM; Zhou H
Int J Clin Pharmacol Ther; 2010 Sep; 48(9):596-607. PubMed ID: 20860913
[TBL] [Abstract][Full Text] [Related]
15. Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program.
Yapa SW; Roth D; Gordon D; Struemper H
Lupus; 2016 Nov; 25(13):1448-1455. PubMed ID: 27072354
[TBL] [Abstract][Full Text] [Related]
16. Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNα antibody, in systemic lupus erythematosus.
Yao Y; Higgs BW; Richman L; White B; Jallal B
Arthritis Res Ther; 2010; 12 Suppl 1(Suppl 1):S6. PubMed ID: 20392292
[TBL] [Abstract][Full Text] [Related]
17. Population Pharmacokinetic and Pharmacodynamic Analysis of Belimumab Administered Subcutaneously in Healthy Volunteers and Patients with Systemic Lupus Erythematosus.
Struemper H; Thapar M; Roth D
Clin Pharmacokinet; 2018 Jun; 57(6):717-728. PubMed ID: 28887801
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and pharmacodynamic relationship of AMG 811, an anti-IFN-γ IgG1 monoclonal antibody, in patients with systemic lupus erythematosus.
Chen P; Vu T; Narayanan A; Sohn W; Wang J; Boedigheimer M; Welcher AA; Sullivan B; Martin DA; Ruixo JJ; Ma P
Pharm Res; 2015 Feb; 32(2):640-53. PubMed ID: 25213774
[TBL] [Abstract][Full Text] [Related]
19. Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis.
Ng CM; Lum BL; Gimenez V; Kelsey S; Allison D
Pharm Res; 2006 Jun; 23(6):1275-84. PubMed ID: 16715358
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis.
Sutjandra L; Rodriguez RD; Doshi S; Ma M; Peterson MC; Jang GR; Chow AT; Pérez-Ruixo JJ
Clin Pharmacokinet; 2011 Dec; 50(12):793-807. PubMed ID: 22087866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
